Nasdaq · Healthcare

Prelude Therapeutics Inc (PRLD)

As-reported financials and recent SEC filings for Prelude Therapeutics Inc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$12.1M

Net income

$-99.5M

Net margin

—

Diluted EPS

$-1.29

ROE

-145.0%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$12.1M	$7.0M	—	—	—
Gross profit	—	—	—	—	—
Operating income	$-104.6M	$-139.7M	$-132.3M	$-123.5M	$-113.7M
Net income	$-99.5M	$-127.2M	$-121.8M	$-115.4M	$-111.7M
Diluted EPS	$-1.29	$-1.68	$-2.02	$-2.44	$-2.43

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-10

42026-06-10

42026-06-10

42026-06-10

42026-06-10

42026-06-10

8-K2026-06-10

10-Q2026-05-12

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on PRLD

Search Prelude Therapeutics Inc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.